Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Mifepristone (RU 486): present status, prospectives]

R Peyron, A Ulmann, E E Baulieu

    Presse Medicale (Paris, France : 1983)
    |February 11, 1995
    PubMed
    Summary

    Mifepristone, a progesterone and glucocorticosteroid receptor blocker, offers diverse therapeutic uses beyond pregnancy termination. Its applications extend to gynecological conditions, labor induction, and potential cancer treatments.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Molecular determinants of the recognition of ulipristal acetate by oxo-steroid receptors.

    The Journal of steroid biochemistry and molecular biology·2014
    Same author

    [Misoprostol: Why Gymiso?].

    Gynecologie, obstetrique & fertilite·2006
    Same author

    The pharmacokinetics of 750 microg levonorgestrel following administration of one single dose or two doses at 12- or 24-h interval.

    Contraception·2002
    Same author

    Levonorgestrel-only emergency contraception: real-world tolerance and efficacy.

    Contraception·2001
    Same author

    The development of mifepristone: a pharmaceutical drama in three acts.

    Journal of the American Medical Women's Association (1972)·2000
    Same author

    RU486 (mifepristone): mechanisms of action and clinical uses.

    Annual review of medicine·1997

    Area of Science:

    • Reproductive medicine
    • Endocrinology
    • Oncology

    Background:

    • Mifepristone (RU 486) functions by blocking progesterone and glucocorticosteroid receptors.
    • Its efficacy is well-established in early pregnancy interruption, often combined with prostaglandin analogues like misoprostol for improved safety and tolerability.

    Discussion:

    • Mifepristone demonstrates utility in late pregnancy interruptions and for expelling intrauterine fetal demise, potentially reducing prostaglandin-related side effects.
    • Investigational uses include cervical ripening, labor induction, contraception, and evaluating antitumoral activity in meningiomas and breast cancer.

    Key Insights:

    • The dual receptor antagonism of mifepristone underpins its broad therapeutic potential.
    • Combination with misoprostol enhances the safety and patient experience for medical pregnancy termination.
    • Mifepristone offers a strategy to mitigate prostaglandin side effects in specific obstetric indications.

    Outlook:

    • Further research is exploring mifepristone's role in gynecological and obstetrical indications, including contraception and labor induction.
    • Antitumorigenic properties are under investigation for meningiomas and breast cancer.
    • Its anti-glucocorticosteroid effects are utilized in treating Cushing's syndrome, with potential for expanded endocrine applications.

    Related Experiment Videos